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· COMMISSION OF THE EUROPEAN COMMUNITIES 
Brussels, 05.05.1998 
COM(  1998) 290 final 
97/0315 (CNS) 
Amended proposal for a 
COUNCIL RECOMMENDATION 
on the suitability of  blood and plasma donors and 
the screening of  donated blood 
in the European Community 
(presented by the Commission pursuant to Article 189 a(2) 
of  the EC Treaty) \  ' .  .  .  .  . 
' 
.  ' 
Explanatory Memorandum . 
In  November  1997,  the  Commi~sion presented  to  ·Council  the  Proposal  for  a  Council 
Recommendation on the Suitability of blood and  plasma donors and  the screening Of donated 
blood in the European Community (COM(97) 605  fin~ll). Given the attention that has been given· 
by  the  European  Parliament  to  blood  safety  and  self-sufficiency ·in  the  Community,  the 
Commission proposed that it be.consulted.  _-
In.its November IS  1997 letter, the Council consulted the European Parliament. . 
On 15 Janu-ary  1998, the President of the Parliament announced that he hadreferred the proposal  . 
to the Committee of  the Environment, Public Health and Consumer Protection  .. ··.  ' · 
On  18  March, the Committee considered the· Commission proposal and the  rapporteur's draft· 
report~ and adopted the draft legislative resolution. The report was tabled on 19 March.  · 
On  2  April,  the.  E~ropea"n Parliament· a:ppr'oved  the  Commission  proposal ·as ·amended and 
adopted the legislative resolution. 
The Commission has accepted fully or in part 16 0 r  the Parliamenf  s_ 29 amendments and rejected  I 
11. Two.did not affect the original English version;  ·  -·-~  .· 
··>'. 
- <; 
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'.  '.:~ Commission proposal 
COM(97) 605 final 
TilE COUNCIL OF TilE EUROPEAN UNION 
Having  regard  to  the  Treaty  establishing  the  European 
Community, and in particular Article 129 thereaf; 
Having regard to the proposal from the Commission
1
; 
Having regard to the opinion of  the European Parliamenf, 
l ..  Whereas fu accordance with point (o) of Article 3 of  the 
Treaty,.  Community  action  must  ·D.tctude  a  contribution 
towards the attainment of  a high level of  health protection; 
2..  Whereas· the  Commission's Communication  on  Blood 
Safety and Self-sufficiency in the Eur-Opean  Communityl of 
December  1994 identified the need for  a blood strategy  in  . 
order  to  reinforce  confidence  in  the · safety  of the  blood . 
transfusion ch~  and promote Community self-sufficiency; 
· J.  Wllereas  Council in  its  Resolution of 2  June  l995
4
,  in 
response to the Commission's Communication,  invited it to 
submit  appropriate  proposals  · in  the  framework  of 
development of  a blood strategy; 
4.  Whereas  Council  in  its  Resolution  of  12  November 
I  996s- on· a strategy towards blood safety and self-sufficierlcy 
fu  the  European. Community  invited  the  Commission  to 
submit proposals  as  a  matter of urgency  with  the  view  to 
encouraging the development of a co-ordinated approach to 
the safety of  blood and blood products; 
5.  Whereas the  European  Parliament in its resolutions  on 
blood safety  and  self-sufficiency  through  voluntary  unpaid 
donations in the European Communit:y6 
7  8  9 has stressed the 
importance .of ensuring  the  highest  level  of safety  in  the 
selection  of donors  and  the  testing  of donations  and  has 
reiterated  its  continued  support  fqr  the  objective  of 
Community self-sufficiency; 
6.  Whereas  Council  Directive 89/381/EEC
10  extended  the 
scope of pharmaceutical legiSlation  to  guarantee the quality, 
safety,  and  efficacy  of  proprietary  industrially  prepared 
medicinal  products  derived  from  human  blood  or  human 
plasma; whereas it does not apply to whole blood, to plasm·a, 
or to blood cells of  human origin; ·  · 
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Modified proposal 
-
) 7.  Whereas therapeutic use. of.blood and medicinal products 
derived  from·  human · blood  and  plasma ·  contributes 
· significantly to saving lives and yields considerable benefits 
for those suffering from long term blood di!;orders; whereas, 
however;  in  spite  of their  significant  therapeutic  value, 
blood, blood components, and blood and plasma derivatives 
have the potential to.transmit infectious diseases; 
8.  Whereas the availability of blood and plasma used for 
therapeutic·  purposes  and  as  starting  material  for,  the 
' manufacture  of medicinal  products ' is  dependent ·on the 
willingness and generosity of Community citizens who are 
prepared to donate; 
9.  Whe~ea5  donations should be voluntary and unpaid; 
10.  Whereas, in  respect  of bloo4  or  plasma  as  a  starting 
material  for  ·the  manufacture  of  proprietary · medicinal 
products, Article 3 of  Council Directi~e 89/381/EEC refers to 
measures:  ·covered  by  the  modification,  as·  ·to  testing 
requirements, referred to 'in Article 6 of  that Directive, to be 
·taken  by  Member · States  to  prevent  the  transmission · of 
infectious .. diseases, · comprising·  the  application.  of  the 
monographs  of  the  European  Pharmacopoeia  and  the 
recommendations of the Council of Europe -and  the  World 
Health Organization as regards in particular the selection and 
testing of blood and plasma donors; tO  promote CommunitY 
self~sufficiency in  human_blood  or human  plasm~; and  to 
encourage voluntary unpaid donations ofblood and plasma; 
II.  Whereas it is not always possible to know at the time 'of 
whole blood or piasma collection which donation may be 
used for further manufacture rather' than used in· transfusion; 
/ 
12.  Whereas  all  blood  and  plasma  used  for- therapeutic  12.  Whereas  all  blood  and · plasma  used  for 
purposes, whether for transfusion or for further manufacture  therapeutic purposes, whether for transfusion or for 
into  industrially-prepare~. medicinal  products,  should  be  further  manufacture  into  industrially~prepared 
obtained from individuals whose health status is such as to  medicinal  products,  should  be  obtained  from 
ensure that transmission of disease does not take place, and  individuals whose health statu~ is such as to minirriise 
that  each  and  every- blood  donation  should  be  tested  in  . the  risk  of infectious  agents  being  transmitted  by 
accordance  with  rules  which  provide  assurances  that  all,  blood; whereas each and every blood d~nation should 
necessary meaSures ·h~ve been taken to safeguard the health '  be. tested  iD'  acc9rdance  with  rules  which  provide 
of  Community citizens who are the recipients of blood and  assurances  that  all ·wecessary  measures  have  been 
blood products;  . taken to safeguard ttfe health of Community citizens 
·_ who· are the recipients of blood and bloo~  products; 
13.- Whereas given that the blood transfusion systems  in  the 
Member States of  the European Community exist to serve_ its 
citizens, it is necessary to secure their confidence in the safety · 
of  these systems; 
14.  Whereas disparities in policies and practices among.the 
Member States  regarding  the  selection of donors  and 'the 
screening of  donations within the Community are such as to 
undermine confidence among its citizens as well as  bloo~ 
transfusion  services  in  the  safety of the  blood and blood 
·products and hinder the achievement of  self-sufficiency; 
15.  Whereas  the  goal· of Community  self-sufficiency  can 
_only  be  achieved through  co-operation  among  the  Member 
States in order to overcome such disparities and build mutual 
confidence  in  all  aspects of safety  of the  blood  transfusion  . 
chain;  -, 
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.  / 16.  Whereas the suitability of an individual to donate blood 
and plasma is  an essential· component in contributing to the 
safety of blood and blood products and·'to the goal of self-
sufficiency; 
17.  Whereas  it  is  essential  that  all  measures  be  taken  to 
safeguard the health of those who provide their blood and 
plasma  and  to  minimise  the  hazard  of transmission  of 
infectious diseases by blood or blood products; 
18.' WhereaS  uniformity  and  consistency  throughout  the 
Community  in ·the  acceptance  of donors,  the  screening  of 
donations  and  the  recording  of relevant  data  will  help  to 
contribute  to  the  achievement  of self-sufficiency  and  to 
increasing  confidenC?e  in  the  safety  of blood  and  plasma 
donations and the transfusion process;  whereas in order to 
bring  about  such · uniformity  and  consistency,  and  build 
confidence, measures are required at Community level; 
19.  Whereas measures at Community level should take into 
account existing guidelines, recommendations and standards 
· in the area of  blood at both national and international levels; 
20.  Whereas in accordance with the principle of  subsidiarity, 
any new measure taken in an area which does not fall within 
· the exclusive competence of the Community, such as_ donor 
suitability and testing of donations, may be taken up by  the 
Community only ii,  by reason of the scale or ~ffects of the. 
· proposed action, the objectives of  the proposed action can be 
better-achieved by- the Community than by Member States; 
Whereas  commonly  agreed  requirements  on  donor. 
suitability and testing of donations  need,  therefore,  to be 
introduced in order to contribute to  the safety of donated 
blood and plasma and the health protection of  donors and to 
permit -confidence· in safety of  the transfusion chain among 
citizens, especially as they move about in the Community, 
and  to  contribute  to the  attainment  of Community  self-
sufficiency as provided for in Community legislation; 
.  21.  Whereas  in  · accordance  with  the  principl~;  of 
proportionality, the means to be deployed at Community level 
for promoting sound practices and consistency throughout the 
Community in the_ suitability of  blood and plasma donors and 
the screening of donated blood. must be _in  proportion _to  the 
objective pursued;  · 
22.  Whereas recommendations_ by the Council,  pursuant to 
Article  129-of the  EC Treaty, are the appropriate means for 
doing so at Community level; whereas such recommendations 
must  be  congruent  with  the  provisions  of  Directive 
89/381/EEC; 
23 ..  Whereas  recommendations  on  donor  suitability  and 
testing requirements form part of  a strategy to enhance safety 
of the blood transfusion chain, the other elements of which 
include the inspection and accreditation of blood collection 
establishments, requirements related to quality assurance of 
the processes involved, the optimal use of blood and blood 
products, haemovigilance, and public awareness; 
24.  Whereas it  is  necessary thaf the best possible scientific 
advice is available to the Community in relation to the safety 
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of  blood and  ~lood products; . 
25·. ·Whereas· Directive  95/46/EC''  on  the  protection  of -
individuals with  regar~-to the  processing of personal  data 
and  the  free . movement  of such  data  lays  down  special 
requirements for ttie prqcessing of data concerning health; 
·HEREBY RECOM~ENDS,THAT 
I.  DEFINITIONS  ·.-' 
For  the  purpose  of this  Recommendation,  Member  States 
assign  to  the  terms  listed  in .Annex  l the meaning .given  to 
,  them therein;  ·  · 
2.  PROVISION  OF.  INFORMATION  TO 
PROSPECTIVE DONORS · 
Member States provide to all ·prospective donors of blood 
_or plasma:  :  ·  -· · ·  ·  ·  .  ·  .  · .  ·  .  ·  · 
2.1  For dorior awareness 
a.  Accurate  but  generally  understandable  educational 
materials about the essentilil nature of blood;· ttie  products' 
detived  from  it, and the  importlmt beilet'its  to  patients  of 
blood and plasma donations;  · 
.  b  .. The reasons for requiring a medical history, physical 
-examinat_ion·,  and the testing o(donations; information. on 
the  risk  of infectious  diseases thaf  may be  transmitted  by · 
blood  and  blood  products;  the.  signs  and  symptoms  of 
Arbs,  and  the  significance  of 'informed. consent',. self~ 
deferral, and temporary and permanent deferral; 
c. · Th~ reasons why they should not donate which may 
be detrimentalto their own health; 
d.  The reasons  why they should notdonate which  ptit 
recipients  at  risk,  such  as  unsaJe  sexual  behaviour,  IHV 
/AIDS,  hepatitis,  drug addiction and the  u~c and  abus.e  of· 
drugs;  ·  . 
e.  The  option  of chariging  their  mind  about  donating 
prior  to  proceeding  .-·.  further  without  '' ariy  ' undue 
embarrassment or discomfort; ·  · 
f.  · Information  on  the  possibility  of withdrawing  or 
self-deferring.at any time during the donation proce~s;  · 
g.  The opport~nity to ask questions at any time; 
·_h.  The undertak-ing thatiftest results shows evidence of 
any  pathology,  they. will  be  contacted  by  the  blood 
collection centre;  '  .  ' 
II  O.J.  N<•  L2X I, 23.11.95, p.JI 
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25a. Whereas  it  has  been  recognised  that, ·although 
still theoretical, there may be a risk of nvCJD being 
transmitted by blood and blood products;. whereas  it 
is  ··,  necessary  to  '·take  appropriate  precautionary' 
measures~  .. · 
.J 
·,·.' 
.· ... 
f / 
i.  Specific information on the nature of the procedures 
involved  in  the  donation process and associated risks  for 
those  willing  to  participate  in  apheresis  programmes, 
whether for plasma or cellular components. 
1.2 Confidentiaiity 
7 
a.  The  measures taken to ensure .the confidentiality  of: 
any  health-related  information  provided  to .. the  authorised 
health personnel, the results of the teSts on their donations, as 
well as ariy future traceability of  their donation;  ·  · 
. b.  The  assurance  that  all  interviews  with  prospective 
donors are carried out in private; 
c.  The  option  of requesting  the  medical  staff of the 
blood collection centre not to use his I her  d~natiori. 
3.  INFORMATION  REQUIRED  FROM 
PROSPECTIVE DONORS 
· Member  States  ensure.  that,  upon  agreement  _of  a 
willingness  to  proceed  to  donate  blood  or  plasma,  all 
prospective  donors  (whether  first  time,  new,  repeat  or 
regular)  provide  to  the  blood  and  plasma  collection  : · 
establishment: 
3.1 Identification 
Identification,  supported  by  valid  official 
documentation providing name (first and surname), address, 
and date of  birth. 
3.2 Health history 
a.  Information  on  their  health  and  medical  history 
including any relevant social and behavioural characteristics 
that may assist in identifying and screening out persons whose 
donation cou~d present a higher risk of  transmitting infections 
as well as those who could have contracted a recent infection 
that may not yet be detectable in the screening tests; 
b.  Answers to questions about their health and medical 
history by way of a  written questionnaire and a  personal 
interview  with  a  trained  health  care  staff member which 
should address the elements and risk behaviours  listed  in 
Annex 2:  . 
c.  Their  signature  and  that  of the  health  c11re . staff 
member  conducting  the  irterviews  on  the  donor 
·questionnaire acknowledging that the educational materials 
provided have been read and understood, the opportunity to 
ask questions has been presented, and satisfactory responses 
have beer1 received;  · 
3.31nformed consent 
a.  Their informed consent in. writing that they wish to 
proceed with the donation process; 
b.  ·.The prospective donor's agreement that if  their blood 
or plasma donation  becomes excess to the  needs  of their 
own Member State, it may be shared with another Member 
State of  the Community that is in need ; 
6 
a.  Information on their health and medical history 
including  ·any  relevant  social  · and· . behavioural 
characteristics  that  may • assist  in  identifying  and · 
screening out persons whose donation could present a 
risk  of transmlttitig .infections  as  well  as  those  who 
could have contracted a recent infection that ml)y not 
yet _be detectable in the screening tests; 
) 
t·.·· '  c 
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4.  REGISTRATION OF DONOR 
· Member States, in order to facilitate future verification of 
. repeat and  regular donors,  _future  tracing ·of donations;  and. 
. future  exchanges  of  info~ation1  establish . a  mutually 
compatible donor identification I registration system to:  . 
Me!Jlber  States,  in  order  to  facilitate  future 
verification of  repeat and regular donors, future traCing · 
of donations,  and  fu~e exchanges  of iJlformation
1 
. establish a mutually compatible donor identification 7 
'  regis!fa~ion  s~stem, taking. fully  into  account  those 
atready existing, to: 
4~1 Donor centre identification 
a.  Permit every donation centre in each Member State to. 
be  uniquely  identified,  by  communicating  to  all·  other . 
Member States and to the Commission a  list of centres arid 
their identificationwmprising the couritry code and a suitabie 
combination ofletters and numbers at  their dis~retion; 
4.2 Donor identification and registry 
a.  Require  that  al·l  relevant  information  regarding  the 
identification  o( prospective  donors  ·be  recorded  in  an 
automated· or manual system  for new  and  flfSt  time  donors·· 
and be verified prior to· each donation for repeat and regular 
donors;  .  ·  · 
,  b.  Provide  for  the  keeping  of records  on  donors  and 
prospective  donors · in  such· a  way  as  to  ensure  unique 
identification,  protect '  th.e  identity  of  the  doh  or:  'froni.. 
unauthorised access· to confidential information,. but facilitate 
· future traceabilitY of  any  donation;  ·  · 
. c.  Allow  for  the .  inclusion  of information  related  to 
' adverse donbr reaction to the donation, reasons for: preventing  . 
.  an  individual  from . donating, : whether  on  a  temparary  or 
. pcmnanent basis while ensuryng confidentiality.'  ' 
5.  DONOR StJITABILITY 
Member  States,.  in  ~ order  .  to  ens  \Ire  the  suitability  of 
individuals to be accepted as donors of  blood ·and plasma: 
'  ,.- . 
S.l Suitability  sr~teria for the acceptance of  whole blood 
imd .apheresis plasma donors 
.  a.  . Ensure  that  general .criteria  for  the  acceptance  of 
blood  and plasma _donors  are  clearly spelt out  in· eyery 
donation ·centre and that clear  messages· are  presented  to 
donors as to the importance of their willingness to donate 
but also the importance of  the acceptanc~ 'criteria; 
b.  E~surethatthe responses given to the issues raised  in 
the written questionnaire and /or the personal interview, as 
presented iri .Annex 2, provide the necessary confidence that 
the donation will  not adverSely affect the health of a  future 
recipient of  the products derived from that donatio~; 
- c.  Ensure that the prospective donor meets the physical 
requirements criteria contained in.Annex.l in order that there 
are no detrimentai effects to his I her own health as the result 
·ofthe donation; 
d.  Ensure  tha( the  prospective  donor's  suitability  is 
determined at e!lch donation session; 
7 
a.  Permit every don!ltion centre in each Member · 
State to  be uniquely  identified,  by communicating to 
all other Member States and.to the Commission a·list 
of centres  and  their·  identification. comprising  the 
country code and a  suitable combination of letters and 
numbers  at their  disc~tion, while  taking  fully  into 
accountthose systems already existing; 
•  <; 
---:' 
.·:.,_. 
·.\ ' e.  Prohibit  or  phase  out  the  practice  of  using 
'replacement donors'; 
.  .  ' 
f.  Require ·the  responsible_  physician  to. give  .. his  I  her 
written  authorisation  as· to  the  final  determination  of the 
suitability  of :a.  prospective  donor,  when  this  may  be 
-questionable. 
6. 
Member States, in order to ensure that the prospective donors 
.  do not cause harm to their own health. nor that their donation 
present a risk of  transmission of  infectious diseases: 
6.1 Deferral crit~ria for ~b~le.blo'od and apberf?sis_plasma · 
dono·rs 
a..  ~nsure those who may show evidence of one of the -
· characteristics listed in Annexes 4 and 5 should be rendered 
either permanently or temporarily ineligible to donate blood 
and plasma; .  · 
· b.  Ensure that appropriate provisions are in place in the 
donation  centre  for·  counselling,  as  appropriate,  to· 
prospective donors who are deferred. .  · 
· 6.2 Deferral registers 
. a.  Maintain a record of any prospective donor deferral, 
whether  permanent  or  temporary,  .including  the  reasons. 
_why;  ·  '-
b.  Ensure that -such  donor deferral registers are set up 
so as  to  fully respect data confidentiality requirements. but 
be available for consultation by authorised personnel of the 
blood  collection  establishment  or  appropriate  authorities 
when matters of  safe~  are concerned. 
7.  DATA PROTECTION 
Member States, in order to ensure the confidentiality of 
sensitive medical information about prospective donors:  .. 
. .  ' 
·. 
c..  Ensure that epidemiological data on viral markers 
are  regularly  collected, analysed. and verified using 
common defmitions, and criteria that are comparable 
··  throughout  the  Community, ·and  that  they  remain 
vigilant for the emergence of  new markers;  ..... 
d.  Ensure that criterja on the nature and duration of . 
deferral are based 0  the results of sound scientific 
evidence, which w  have to be promoted,· and that 
the precautionary principle should prevail when that 
evidence is not available; 
.  a.  E.nsure  that  measures  are  in  place  for  prospective  · a.  Ensure that measures are in place for prospective 
.donor identification and accurate data verification;  ' '  donor identification and accurate data verification ~ 
means of  a unique coding system; 
b.  Ensure  that data  security measures are  in  place  as 
. well  as  safeguards  against  unauthorised  data  additions,  · 
deletions  or . modifications  to  donor  files  or  deferral  · 
registers, and transfer of information; 
c.  Ensure that procedures are  in  place to _resolve  data 
discrepancies;  · 
8 
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_  d.  Prevent · the  unauthorised  disclosure  of  such 
- infonn~tion, while ensuring the traceability of  donations; 
e.  Pay  particurar  attention  to  compli!lnce  with  the 
requirements of Directive 95/46/EC iri  particular its Article 
8, when processing data related to blood and plasfua donors: 
8.  . VOLUMES ·COLLECTED .FOR  SAFETY  OF 
DONOR, 
To protect the health of  the donor, Member States: 
a.  Adhere . to  the  maximum  volumes  _of  blood  and 
plasma collected at a  single" donatiol"l and over a  12 month  ( 
period presented in Annex 6;  · 
b.  Adhere  to  the  minimum  time  intervals  between 
donations as presented in Annex 6; 
c.  Ensure tl)at medical attention is available to the donor in 
the event of an adverse event related to. the donation. 
9.  -TESTING SAMPLES OF DONATED Bl..OOD 
Member States, in order to en'sure the safety of all blood 
and plasma donations: 
a.  Ensure  that  a  sample· of  all  donations  whether 
intended  for  transfusion:  purposes  or  for  further 
manufacturing into industrially prepared medicinal products 
is  tested  for  diseases  transmissible  by  blood ·using  licensed 
screening tests to eliminate units that are repeat reactive;  · 
b.  Ensure  that · all  blood  donations  be  found  non-
reactive  for  the  transmissible  disease  markers  listed .in 
Annex 7; 
c.  Require re-testing of the blood samples found to be 
reactive  in  an initial screening test in  aC<:ordance  with  ti}e 
general algorithm set out  in Annex· 8;  · 
10.  ADDITIONAL MEASURES 
a.  Member  States  take  the  necessary  steps  for  the. · 
dissemination  of' this  recommendation.·· to  all  parties 
concerned, and in particular to ·blood establishments in their _ 
territory;  · 
b. · Member.  States  take  ·all  necessary.  measures  to · 
encourage the  voluntary and  unpaid donation. ofblood or·· 
plasma;  · 
9 
b.  Ensure that all blood and·plasma donations be 
fourid  non-reactive  in  approved  screening  tests  for  ··~ 
the transmissible disease markers listed in Annex 7;  .  .  ' 
-
) 
c. ·.  Member  States . take  appropriate  measures  to  · 
minimise any hazard that might arise that is relevant 
to  the  possible  transmission  of nvCJD  via  blood 
.  components and manufactured plasma~derivatives;. 
d.  Member States take the necessary steps· to collect,·. 
analyse, . publish  and  .  update  epidemiological· ·data 
usirig  common. definitions,·  and  criteria  that  arc 
comparable throughout the Cortununity. INVITES THE COMMISSION 
To  report  ori  the  application of these  ~commendations and 
keep the matters covered therein under review in order to take 
the necessary steps for revision and updating. 
Done at Brussels  For the Council 
The President 
10 
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\ ANNEXl 
·Common Terminology 
Blood  Whole blood collected from a single donor and 
processed either for transfusion or further manufacturing  · 
Blood product  Any. therapeutic ·product derived 'from 
human wh?le blood or plasma donations. 
Blood component  . Therapeutic  components  of 
blood  (red cells, white  cells;  plasma, platelets)  that  can  be 
prepared  by  centrifugation,  filtration,  and  freezing · using 
conventional blood bank methodology. 
Plasma derivative  Highly  purified  human  plasma 
protein  prepared  under  .  licensed  ' pharmaceutical. 
manufacturing conditions 
Cell-derivative  A therapeutic product derived from 
a  blood  component  (as  derived  from  leukocytes  - · 
interferon,  cytokines  -· or .  from  outdated  erythrocytes  - · 
haemoglobin solution) 
Donor 
First time donor  Someone  who  has_  never  donated 
either blood or plasma. 
Deferred aonor  Someone who,  for. protection· of their own 
health  or  that  of potential· recipients  of blood  products 
prepared  from  his  I  her donation,  is  not permitted  to  give 
blood or plasma. 
Lapsed donor  Someone  who  routinely  had 
donated  blood  or.  plasma  (regular  donor)  and  has  stopped 
presenting himself I herself to donate.  · 
New donor  Someone who  has not donated 
blood or plasma within the last year or ·is not listed  in  the 
local donor registry.  ·  · 
·Prospective ·donor  Someone who  presents· himself 
I herself at a blood or plasma collection establishment and 
states his/ her wish to give blood or plasma.  · 
Repeat donor  _Someone  who  has  domited 
before and within the last year in ihe same donation centre.-
Regular donor  Someone who routinely donates 
. their blood_or plasma at the permissible time intervals. 
Replacementdo~or  Donors  recruited  by  patients  to 
enable them to undergo·eJective surgery._ 
Medicinal product derived from blood or plasma  _ 
Same ~eaning  as in Directive 89/38 1/EEC 
Suitability  Process  by  which  an  acceptance 
decision of  a prospective blood or plasma dpnor can be made. 
Personal data  Any  information· relating to  an identified 
or identifiable natural person who can be identified, directly 
or indirectly,  in  particular by- reference to  an  identification 
number  or  to·  one  or  more  factors  to. his  physical, 
. physiological, mental, economic, cultural or social identity. 
(Directive 95/46/EC) 
Voluntary~ unpaid blood donation  · 
Same meaning as in Directive S9/381/EEC  '  · 
ll 
J ANNEX2 
Common Elements to be Covered in a Donor 
·Questionnaire 
•  Indication  that  the  questionnaire  is  to  be  completed, 
sig~ed and dated• 
• ·  General health of  the donor 
Whether prospective donor 
•  has recently consulted a doctor 
•  is taking any medication 
•  has haemophilia or related blood clotting disorders 
•  participates in hazardous sports (e.g. motor racing) 
•  undertakes  employment  that  might  cause  problems 
within 24 hours after blood donation 
•  is  pregnant or has  delivered a child now  under  I  year 
{for women) 
•  has  received  growth  hormone  or  pituitary  extract 
treatment 
•  has received a blood transfusion 
• .  has had a corneal or dura mater transplant 
•  has undergone tattooing, acupuncture, body piercing by 
someone other dian qualified and I or licensed professional 
•  haS  been in  recent contact (<3  weeks) with contagious 
infections, chicken pox, measles  . 
•  has · recently  ·received  a  vaccination(polio,  tetanus, 
holiday vaccinations) 
•  has  re<:ently  (<5  days)  ingested  aspirin  (or other  pain 
killers) 
•  is working as a prostitute 
•  is HIV positive 
•  has a spouse who is HIV positive 
•  has a family history ofCreutzfeldt-Jacob disease (CJD) 
•  self-injects drugs  . 
Whether prospective donor has I had 
•  Brucellosis 
•  Epilepsy 
•  Hepatitis · 
•  Jaundice 
•  Major surgery/serious illness 
•  Malaria 
Whether pr.ospective donor has travelled 
•  Outside Western Europe & North America 
•  Men who have sex with other men 
•  Sexual activity in Africa· 
•  Sexual  activity  in  countries other than those  in  Africa: 
(to specify country) 
•  Self-exclusion option 
I 
· The.questionnaire has to be given and completed at every visit. 
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•  has  sexual behaviour that places them  at risk of 
transmitting infectious diseases _ 
•  ~as a tiip9WSi ucJ:ig  i&  WI'' p9sitiJ;'I 
-
~) 
Whether prospective donor has travelled 
•  outside the European Community (individual 
countries may be specified) 
Whether prospective donor has I had 
•  Sexual behaviour that places them at risk of 
transmitting infectious diseases 
•  Sexual · · activity.  outside  the  European 
Community  (individual  countries  may  be 
specified) 
•  ~IIXUaJ  aQ&juj~' iR  Q9WR&riiiS  9&~11F  t~aR tR9SII 
iR Afi:iQai  ~9  spe<Wi9' Q9WR,F)') .  I 
ANNEX3 
Common Acceptance Criteria for Blood and Plasma 
D~nors 
Age·  . 
Blood and plasma donors should be  18.- 65  years of age. 
Acceptance  of first  time ·donors  age  60  - · 65  is  at  the 
discretion of the responsible physician. Repeat donors may 
. continue tQ donate ~~:fter the age of  65 with the permission of 
the responsible physician given annually. 
For whole blood, donors aged 17, and not legally classified 
as  minors,  may  be  accepted;  otherwise  written  consent 
should be required according toapplicable law. 
Body weight 
Donors weighing no less than 50 kg may donate whole 
blood or plasma. 
Blood pressure 
The systolic blood pressure should not exceed  180 mm  of 
· mercury and the diastolic pressure should not exceed  100 
mm of  mercury.  ·  · 
Pulse  _:,.;  ~·· 
- The pulse should be regular and between 50 - 110 beats per 
minute.  Those  prospective  donors  who  undergo  intensive 
spoit training and have a pulse rate lower than 50 beats per 
minute may be accepted.  · 
Haemoglobin 
The haem~globin concentration should be determined prior 
to  donation  and  shall  be  no  less  than  ,12.5  g/100  ml  for 
females and  13.5  gliOO  ml for males (or equivalent values 
expressed~  in· mmol I  l).  For apheresis  pl~ma donors,  the 
minimum  shall  be  1'2.5  g/100  ml  for  both  males  and 
females.  · 
Haematocrit 
-
Haematocrit  J 
~. 
The packed cell volume (haematocrit) should be determined  Where the haemoglobin concentration has  not been 
prior to donation and shall be no less than 38% for females  determined,  the  packed' cell  volume  (haematocrit) 
and  40%  Tor  males.  For  apheresis_ plasma  donors,  the  . should be deiermined prior to donation and ,shall be· 
minimum shall be38%.  -no less than 38% for females and 40% for males. For' 
Donation interval 
For  whole  blood,  ·the  time  interval  between  donations 
should be greater than 8 weeks. 
For  apheresis plasma, this  interval should not be  less  tl'ian 
72 hours. 
Donation frequency 
For whole blood, the maximum number of times allowable 
for donations should be 6 I year for men, 4 I year for women 
and 3 I year for pre-menopausal donors.  r 
.. F:or  apheresis  plasma,  the  maxi~um,donation frequency 
should be twice per week, 
13 
apheresis plasma donors; the mi'nimiim,shall be 38%  .. ANNEX4 
Common Deferral Criteria for Blood and Plasma 
Dori~rs 
(For protection of  donor) 
. 1.  Permanent deferral 
Prospective  donors  with  any  or a  history  of any  of the_ 
following  should  be  declared  permanently  ineligible  to 
donate  blood  or plasma  for  the  protection  of their  own 
health:  ·  · 
•  Auto-immune diseases 
•  Cardiovascular di.seases . 
"  Central nervous system diseases · 
•  Malignant diseases. 
•  Abnorrn'al _bleeding tendency 
•  Fainting spells (syncope) or convulsions 
Permanent deferral in cases where prospective donors have 
or  have  had  a  severe  or  chronic . gastrointestinal, 
haematological, metabolic, respiratory, or renal disease,  n<;Jt 
included. in· the ·preceding categorie·s, shOuld be determined 
by  a  qu~lified  physician  in  · the  blood  collection 
establishmen~. 
Temporary deferral 
Ineligible for 1 year 
•  Abortion 
•  Pregnaltcy (after delivery) 
· NOTE:  Additional  reasons  may  exist  for  the  temporary 
deferral of a donor for the protection of their own health.  A 
decision as. to length of  time is at the discretion of  a qualified 
physician in the blood collection establishment. 
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-.' ANNEX5 
Common Deferral Criteria for Blood and Plasma 
Donors 
(For protection of recipient) 
1.  Permanent deferral 
Prospective  donors with any,  or a history of any, ·of  the 
following  should  be  deClared  permanently  ineligible.  to 
donate_  blood  or  pla,!lma  for  the  protection. of potential 
recipients~ 
• ·  Auto-immune diseases 
o  Infectious diseases- persons suffering or having suffered' 
from 
Babesiosis 
·.  Brucellosis 
Creutzfeldt Jacob  disease  (CJD)  (persons  in  whos.c 
family this has occurred) 
Hepatitis B (HBsAg confirmed positive) _ 
Hepatitis C 
Hepatitis, infec!ious (of  unexplait!ed aetiology) 
HIV/ AIDS 
HTLVI/ II 
Leprosy 
Kala Azar (leishmaniasis) 
Q fever 
Syphilis 
Trypanosoma cruzi (Chagas' diseas~) 
'  '-
.  o  Malignant diseases  ' 
•  Alcoholic, chronic 
o  Cornea I dura mater transplantation recipient 
•  IntravenoUs (IV) drug use 
•  Males who have sex with other males 
•  PitUitary  hormone  of  human · origin  (e.g.  growth, 
hormone) recipient  - · 
o  Prostitutes (m~Ie and female) 
2.  Temporary deferral· 
Prospective  donors  with  any  of the  following  conditions 
shoul!l-be  declared  ineligible  to  donate  blood  or  plasma 
temporarily~ The time interval for deferral varies accordiltg 
to  th~ condition.  · 
2.1  hicligible for 3 years 
o  Tuberculosis (after recovery) 
·.J5 
l-
J 
'. 
) 2.2  Ineligible for 1 year 
•  · Accidental ,exposure  to  blood  or  blood  contaminated 
instruments 
•  AcupunctUre (if  not performed by a qualified physician) 
·•  Blood transfusion rec_ipient 
•  Body piercing 
•  Drug allergy (after last exposure) 
•  Tattoo 
•  T(;ixopta5mosis (after recovery) 
•  Individuals who have had sexual relations with someone 
infected or at increased risk of infection with HBV, HCV, 
HIV 
2~3  Ineligible for 6 months 
•  Monomicleosis infeetiosa (after recovery) 
•  Surgery, major 
. 2.4  Ineligible for 4 weeks 
•  Following.  administration  of live. attenuated  viral 
vaccines 
2.5·  Ineligible for 48 hours 
•  Following administration of killed I  inactivated viral I 
bacterial and rickettsial vaccines 
•  Following administration of  vaccines (desensitising) 
•  Rabies· vaccine (prophylactic aqministration) 
. 2.6  Ineligible  (time frame variable) 
•  Hepatitis A 
•  ·Malaria (does not apply to plasmapheresis donors) 
•  Prescribed medicines 
•  Tropical diseases (other) 
NOTE:  Additional  reasons  may  exist  for  the  temporary 
·  def~rral of a  donor· for the  protection  of the  recipient.  A 
decision a5 to length of  time is at the discretion of  a qualified  · 
physician in the blood collection establishment. 
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ANNEX6 
Common Volumes to be collected 
and time intenrals 
for whole blood and plasma donations 
Whole Blood 
Maximum Volume  per  donation.  500 ml 
per consecutive 12 month peri~d 
3 litres 
Minimum time interval between. donations  8 weeks· 
Maximum number of  donations per 12 month perio~ 
6 (males)_ 
,  4 (females) 
(3 for pre-menopausal women) 
Automated plasmapheresis 
MaximumVolume  perdonation 
Donor Weight.  Volume Collected 
50~67 kg 
68~79 kg 
(excluding anticoagulant) 
625 ml 
750ml 
so_ kg or-more  800 ml 
Minimum time interval between donations  72 hours 
Maximum number of  donations per 7 day period  2 
.  . '  -
-
·:) 
"".'· 
,·[ ANNEX7 
Com  mol! Testing Requirements for all Blood 
.Samples 
whether a whole blood or plasma donation 
For all blood and plasma donations 
· Antibodies to the Hepatitis C virus  Anti-HCV 
Antibodies to the human immunodeficiency virus 1 
Anti~HIV  t 
· Antibodies to tbe human immunodeficiency virus 2 
. Anti-HIV2 
Surface antigen or Hepatitis B  HBsAg 
- In addition 
For  all,  excluding  plasmapheresis  i~tended  only  for 
.•  .fractionation. 
ABO group .. 
Rh type 
· Malaria  for travellers to endemic areas 
·Treponema palllilum (syphilis) 
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ANNEX·8 
Cominon Algorithm for 
Interpretation ofreactive r~sults in screening tests in relaiion to 
clinical use of  donation and 
Reactive re.sults in supplementary I confirmation tests 
in relation to donor deferral 
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PROPOSAL FOR A COUNCIL RECOMMENDATION 
ON THE  SUITABILITY  OF  BLOOD  AND  PLASMA 
DONORS  AND  THE  SCREENING  OF  DONATED 
BLOOD IN THE EUROPEAN COMMUNITY· 
The proposal for a draft Recorruriendation on the suitability of blood and plasma donors and the 
screening of donated blood in the European Community has no financial  impact either·. on the 
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